According to Fars news agency’s health reporter, Alireza Astaghami, the chairman of the board of directors of the Gabrik Diabetes Association, said in a press conference, referring to the problems in diabetes patients, that about 7 million people, including the number of people in their households, are suffering from type 2 diabetes. There are two.
He continued: In February of last year, the Supreme Council of Insurance approved that some services for diabetic patients should be covered in terms of diagnostic and medicinal tools.
Tasgami added: More than four months have passed since this decree, but it has not yet been implemented, and this decree needs to be approved by the government.
The chairman of the board of directors of Gabrik Diabetes Association noted: Recently, a series of new diabetes drugs have been developed that, in addition to treating diabetes, can control cardiovascular and kidney problems, but due to the lack of insurance coverage and high prices, patients cannot afford to buy these drugs.
He emphasized the need to speed up the approval of these drugs and insurance coverage and said: These drugs do not have insurance coverage and this should be done quickly.
Tasgami stated: Unlike in the past, when we faced a shortage of pen insulin, now we are faced with the diversity of different types of insulin.
The chairman of the board of directors of Gabrik Diabetes Association stated that we want peace in the insulin market in the country and added: policies for insulin should be organized.
Pointing to the high prices and the problem of the needle head and blood glucose test strips in the country, Tasgami said: The lives of type 1 diabetic boys and girls are affected by the insulin drug.
He added: “Insulin and oral diabetes medicines are among the main list of essential medicines of the World Health Organization and governments are obliged to provide them.”
The head of the board of directors of Gabrik Diabetes Association noted: Blood sugar tests should be introduced through their own channel and they should monitor their introduction.
Referring to electronic prescribing, Tasgami stated: Repeating insulin prescriptions should be implemented so that the problem of repeating insulin prescriptions can be solved, so that patients’ dissatisfaction and tension will disappear.
He pointed out that according to the economic conditions, it is necessary to not remove the preferred currency for medicine, he said: “Now, increasing the price of vital medicines without seeing compensation in the insurances creates many problems and requires the agreement of different government bodies.” Is.
The head of the board of directors of Gabrik Diabetes Association said: The possibility of registering patients for certain diseases should be increased and we are ready to help inform these patients.
Referring to the presence of 150,000 type 1 diabetic patients in Iran, Kamran Niko Sokhon, CEO of the Iranian Diabetes Association, said: “Education of diabetic patients is very important and this education is not covered by insurance, so we emphasize this issue in this package.”
Criticizing the insulin distribution system for diabetic patients, he thought: There are many insulins in the market, but when the insulin prescribed by the doctor is not available in the market, a similar one is given, which causes problems.
Referring to the daily control of type 1 patients, Niko Sokhon said: Until now, there is no insurance coverage for blood sugar test and its strips in the main insurances.
He added: Diabetic children need blood sugar test at least three times, but the price of the blood sugar test strip package is very high.
Referring to the obsolescence and non-use of blood sugar tests and the use of new sensors, the CEO of the Iranian Diabetes Association said: “It is not fair for a diabetic patient to pay half of his salary to buy a blood sugar test, and these strips are now in short supply.”
Referring to the monthly cost of more than three million prescriptions for diabetic patients, he expressed: special attention should be paid to the issue of insurance coverage of these drugs so that patients can follow the treatment and do not abandon the treatment halfway.
end of message/
You can edit this article
Suggest this article for the first page